findmyKOL

Pravin Singhal, MD

Basic profile

Feinstein Institute for Medical Research

ORCIDNPI
RegionNew Hyde Park, NY · NortheastSpecialtyNephrologyFocusNephrology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2021Online presenceNot yet checkedPayments2021 onwardNIH funding1991–2021

Pravin Singhal is a Nephrology physician affiliated with Feinstein Institute for Medical Research. OpenAlex indexes 393 publications with 11,854 citations (h-index 54). By OpenAlex citation count, this profile ranks in the top 10% of Nephrology profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
393publications

Distinct works indexed by OpenAlex, matched via ORCID.

11,854citations

Total citations across indexed works.

54h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
6NIH grants · 1991–2021

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

410 Lakeville Rd
New Hyde Park, NY 110421101

Telephone

516-465-5260

Registry record last updated 8 Jul 2007.

View the NPPES registry record

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    53.2%
    Loop diuretic15.2%
    Furosemide78%Torsemide22%
    Part D44 patients
    Calcium channel blocker11.5%
    Amlodipine Besylate55%Nifedipine Er27%Diltiazem 24hr Er (Cd)17%
    Part D<11 patients

    + 9 more classes in this area

  • Metabolism & gastrointestinal

    24%
    SGLT2 inhibitor13.4%
    Farxiga80%Jardiance20%
    Part D56 patients
    H2 blocker2.2%
    Famotidine100%
    Part D11 patients

    + 6 more classes in this area

  • Blood & clotting

    7.7%
    Solutions for parenteral nutrition7.7%
    Calcium Acetate100%
    Part D24 patients
Where care is delivered (Part B)24.7% facility · 75.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

6 NIH research awards on record, funded 19912021 per NIH RePORTER. The latest:

32 more award records behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”